Impact of inflammation on ocular immune privilege

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 155-165

  Mo, Jun Song ^a   Wang, Wei ^a   Kaplan, Henry J ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA;

ANTERIOR EYE CHAMBER; ARTICLE; AUTOIMMUNE DISEASE; BLOOD EYE BARRIER; DELAYED HYPERSENSITIVITY; DISEASE MODEL; EYE INFLAMMATION; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; NONHUMAN; PATHOGENESIS; PIGMENTATION; PRIORITY JOURNAL; T LYMPHOCYTE; UVEITIS; ANIMAL; EYE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNERVATION; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; ANTERIOR CHAMBER; AUTOIMMUNE DISEASES; EYE; HUMANS; IMMUNE TOLERANCE; MICE; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA; UVEITIS;

EID: 33947544464     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099266     Document Type: Article

References (33)

1. Streilein JW: Ocular immune privilege and the Faustian dilemma. The Proctor lecture. Invest Ophthalmol Vis Sci 1996;37:1940-1950.
2. Freddo TF: Shifting the paradigm of the blood-aqueous barrier. Exp Eye Res 2001;73:581-592.
3. Taylor AW, Streilein JW, Cousins SW: Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol 1994;153:1080-1086.
4. Mo JS, Streilein JW: Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur J Immunol 2001;31:3806-3815.
5. Taylor JW: Ocular immunosuppressive microenvironment; in Streilein JW (ed): Immune Response and the Eye. Chem Immunol. Basel, Karger, 1999, vol 73, pp 72-89.
6. Kaplan HJ, Streilein JW: Immune response to immunization via the anterior chamber of the eye. I. F1-lymphocyte-induced immune deviation. J Immunol 1977;118:809-814.
7. Streilein JW, Niederkorn JY: Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med 1981;153:1058-1067.
8. Streilein JW, Niederkorn JY: Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J Immunol 1985;134:1381-1387.
9. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP: Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685-4692.
10. Silver PB, Chan CC, Wiggert B, Caspi RR: The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999;40:2898-2905.
11. Ohta K, Wiggert B, Taylor AW, Streilein JW: Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 1999;40:2010-2018.
12. Kasner L, Chan CC, Whitcup SM, Gery I: The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993;34:2911-2917.
13. Mo JS, Streilein JW: Analysis of immune privilege in eyes with Mycobacteria tuberculosa adjuvant-induced uveitis. Ocul Immunol Inflamm 2005;13:139-147.
14. John SW, Smith RS, Savinova OV, Hawes NL, Chang B, Turnbull D, Davisson M, Roderick TH, Heckenlively JR: Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci 1998;39:951-962.
15. Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze DV, Ksander BR, Streilein JW, John SW: By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med 2003;197:1335-1344.
16. Ohta K, Yamagami S, Taylor AW, Streilein JW: IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2000;41:2591-2599.
17. Ohta K, Wiggert B, Yamagami S, Taylor AW, Streilein JW: Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol 2000;164:1185-1192.
18. Geiger K, Sarvetnick N: Local production of IFN-gamma abrogates the intraocular immune privilege in transgenic mice and prevents the induction of ACAID. J Immunol 1994;153:5239-5246.
19. Adamek-Kotowicz E, Lutjen-Drecoll E: Development of F4/80 positive cells and CGRP nerve terminals in the mouse uvea (abstract). Invest Ophthalmol Vis Sci 2003;44:744.
20. Kitazawa T, Streilein JW: Hapten-specific tolerance promoted by calcitonin gene-related peptide. J Invest Dermatol 2000;115:942-948.
21. Streilein JW, Alard P, Niizeki H: Neural influences on induction of contact hypersensitivity. Ann NY Acad Sci 1999;885:196-208.
22. Levite M: Nerve-driven immunity. The direct effects of neurotransmitters on T-cell function. Ann NY Acad Sci 2000;917:307-321.
23. ten Tusscher MP, Beckers HJ, Vrensen GF, Klooster J: Peripheral neural circuits regulating IOP? A review of its anatomical backbone. Doc Ophthalmol 1994;87:291-313.
24. Rozsa AJ, Beuerman RW: Density and organization of free nerve endings in the corneal epithelium of the rabbit. Pain 1982;14:105-120.
25. UnMer WG: Review: mediation of the ocular response to injury. J Ocul Pharmacol 1990;6:337-353.
26. Bereiter DA, Bereiter DF, Hathaway CB: The NMDA receptor antagonist MK-801 reduces Foslike immunoreactivity in central trigeminal neurons and blocks select endocrine and autonomic responses to corneal stimulation in the rat. Pain 1996;64:179-189.
27. Vega J, Keino H, Streilein JW: Immune privilege in the anterior chamber of the eye is disrupted by removal of the superior cervical ganglion. Fort Lauderdale, American Uveitis Society Meeting, April 24, 2004; www.uveitissociety.org
28. Streilein JW, Bradley D, Sano Y, Sonoda Y: Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci 1996;37:413-424.
29. Wang Y, Hand AR, Gillies C, Grunnet ML, Cone RE, O'Rourke J: Morphologic evidence for a preferential storage of tissue plasminogen activator (t-PA) in perivascular axons of the rat uvea. Exp Eye Res 1997;65:105-116.
30. Peng T, Jiang X, Wang Y, Hand A, Gillies C, Cone RE, O'Rourke J: Sympathectomy decreases and adrenergic stimulation increases the release of tissue plasminogen activator (t-PA) from blood vessels: Functional evidence for a neurologic regulation of plasmin production within vessel walls and other tissue matrices. J Neurosci Res 1999;57:680-692.
31. Yehualaeshet T, O'Connor R, Green-Johnson J, Mai S, Silverstein R, Murphy-Ullrich JE, Khalil N: Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 1999;155:841-851.
32. Mo JS, Streilein JW: Ocular trauma induced a secondary immunosuppressive microenvironment containing active TGF-beta (abstract). Invest Ophthalmol Vis Sci 2005;46:5044.
33. D'Orazio TJ, Niederkorn JY: A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 1998;160:2089-2098.